Moderna (NASDAQ: MRNA) has turned down China's request to hand over the core intellectual property behind the development of its COVID-19 vaccine to China due to commercial and safety concerns, according to a Financial Times report. As a result, the report stated that this led to a collapse of discussions of Moderna's sale of the COVID-19 vaccine in China. However, the report added that the vaccine maker is still "eager" to sell the vaccine to China.
https://www.tipranks.com/news/moderna-refuses-to-sell-its-vaccine-tech-to-china?utm_source=advfn.com&utm_medium=referral